Breaking News

Sunday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Piper Sandler keeps Overweight on Gamida Cell, lowers price target to $7 » 19:16
10/02/22
10/02
19:16
10/02/22
19:16
GMDA

Gamida Cell

$1.58 /

-0.13 (-7.60%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Gamida Cell to $7 from $8 and keeps an Overweight rating on the shares. The analyst notes Gamida Cell issued 12.9 million shares at $1.55 raising gross proceeds $20 million. Additionally, Highbridge Capital provided a $25 million senior secured, 24-month term loan with a 7.5% coupon convertible at $2.22. Tenthoff estimates Gamida Cell now has pro forma cash of $97 million, owes Highbridge $97 million, and has 74.38 million shares outstanding. He remains confident in omidubicel approval for allo-HSCT by the January 30th PDUFA date based on positive Phase III data showing reductions in time to neutrophil and platelet engraftment, infection and hospital stay.

ShowHide Related Items >><<
GMDA Gamida Cell
$1.58 /

-0.13 (-7.60%)

GMDA Gamida Cell
$1.58 /

-0.13 (-7.60%)

08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
05/10/22 Piper Sandler
Gamida Cell price target lowered to $6 from $13 at Piper Sandler
04/26/22 JMP Securities
JMP Securities reiterates Outperform on Gamida Cell as FDA lifts clinical hold
GMDA Gamida Cell
$1.58 /

-0.13 (-7.60%)

  • 28
    Sep
GMDA Gamida Cell
$1.58 /

-0.13 (-7.60%)

Thursday
Conference/Events
William Blair biotech analysts to hold analyst/industry webinar » 14:45
09/29/22
09/29
14:45
09/29/22
14:45
GMDA

Gamida Cell

$1.72 /

+0.09 (+5.52%)

Biotech Analysts, along…

Biotech Analysts, along with Chief Medical & Chief Scientific Officer Simantov of Gamida Cell, discuss innovations in hematopoietic stem cell transplantation on an Analyst/Industry webinar to be held on September 29 at 3 pm. Webcast Link

ShowHide Related Items >><<
GMDA Gamida Cell
$1.72 /

+0.09 (+5.52%)

GMDA Gamida Cell
$1.72 /

+0.09 (+5.52%)

08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
05/10/22 Piper Sandler
Gamida Cell price target lowered to $6 from $13 at Piper Sandler
04/26/22 JMP Securities
JMP Securities reiterates Outperform on Gamida Cell as FDA lifts clinical hold
GMDA Gamida Cell
$1.72 /

+0.09 (+5.52%)

  • 28
    Sep
GMDA Gamida Cell
$1.72 /

+0.09 (+5.52%)

Hot Stocks
Gamida Cell announces long-term data from omidubicel study » 07:11
09/29/22
09/29
07:11
09/29/22
07:11
GMDA

Gamida Cell

$1.63 /

-0.32 (-16.41%)

Gamida Cell announced the…

Gamida Cell announced the presentation of new long term follow-up data and health-related quality of life scores of patients treated with omidubicel at the Tenth Annual Meeting of the Society of Hematologic Oncology, or SOHO, being held in Houston, Texas. The long-term, durable clinical benefit of omidubicel was observed at three years across a patient population that typically has a poor prognosis. A study highlighted long-term follow-up of 105 patients transplanted with omidubicel between 2006-2020. The data demonstrated an overall survival and disease-free survival of 63% and 56% at three years, respectively, as well as durable long-term hematopoiesis and immune competence. Overall well-being health-related quality of life scores for patients treated with omidubicel demonstrated clinical benefit compared to standard of care. A study featured an analysis of 108 patients that completed validated health-related quality of life surveys on screening and days 42, 100, 180, and 365 post-transplant. Measures of physical and functional well-being and other HRQL scores were more favorable with omidubicel. These data suggest clinically meaningful and sustained improvements in physical, functional, and overall well-being compared to umbilical cord blood transplantation.

ShowHide Related Items >><<
GMDA Gamida Cell
$1.63 /

-0.32 (-16.41%)

GMDA Gamida Cell
$1.63 /

-0.32 (-16.41%)

08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
05/10/22 Piper Sandler
Gamida Cell price target lowered to $6 from $13 at Piper Sandler
04/26/22 JMP Securities
JMP Securities reiterates Outperform on Gamida Cell as FDA lifts clinical hold
GMDA Gamida Cell
$1.63 /

-0.32 (-16.41%)

  • 28
    Sep
GMDA Gamida Cell
$1.63 /

-0.32 (-16.41%)

Conference/Events
William Blair biotech analysts to hold analyst/industry webinar » 04:55
09/29/22
09/29
04:55
09/29/22
04:55
GMDA

Gamida Cell

$1.63 /

-0.32 (-16.41%)

Biotech Analysts, along…

Biotech Analysts, along with Chief Medical & Chief Scientific Officer Simantov of Gamida Cell, discuss innovations in hematopoietic stem cell transplantation on an Analyst/Industry webinar to be held on September 29 at 3 pm. Webcast Link

ShowHide Related Items >><<
GMDA Gamida Cell
$1.63 /

-0.32 (-16.41%)

GMDA Gamida Cell
$1.63 /

-0.32 (-16.41%)

08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
05/10/22 Piper Sandler
Gamida Cell price target lowered to $6 from $13 at Piper Sandler
04/26/22 JMP Securities
JMP Securities reiterates Outperform on Gamida Cell as FDA lifts clinical hold
GMDA Gamida Cell
$1.63 /

-0.32 (-16.41%)

  • 28
    Sep
GMDA Gamida Cell
$1.63 /

-0.32 (-16.41%)

Wednesday
Syndicate
Gamida Cell 12.9M share Spot Secondary priced at $1.55 » 06:24
09/28/22
09/28
06:24
09/28/22
06:24
GMDA

Gamida Cell

$1.95 /

+0.03 (+1.56%)

The deal priced below…

The deal priced below last closing price of $1.96. Piper Sandler and JMP Securities are acting as joint book running managers for the offering.

ShowHide Related Items >><<
GMDA Gamida Cell
$1.95 /

+0.03 (+1.56%)

GMDA Gamida Cell
$1.95 /

+0.03 (+1.56%)

08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
05/10/22 Piper Sandler
Gamida Cell price target lowered to $6 from $13 at Piper Sandler
04/26/22 JMP Securities
JMP Securities reiterates Outperform on Gamida Cell as FDA lifts clinical hold
GMDA Gamida Cell
$1.95 /

+0.03 (+1.56%)

GMDA Gamida Cell
$1.95 /

+0.03 (+1.56%)

Over a week ago
On The Fly
Fly Intel: After-Hours Movers » 17:46
09/27/22
09/27
17:46
09/27/22
17:46
FYBR

Frontier Communications

$22.22 /

+0.895 (+4.20%)

, IBIO

iBio

/

+

, IPW

iPower

$1.05 /

+0.1115 (+11.88%)

, BB

BlackBerry

$5.09 /

+0.11 (+2.21%)

, CALM

Cal-Maine Foods

$60.55 /

+0.8 (+1.34%)

, MNMD

Mind Medicine

$6.11 /

+0.37 (+6.45%)

, GMDA

Gamida Cell

$1.95 /

+0.03 (+1.56%)

, SAND

Sandstorm Gold

$5.57 /

+0.19 (+3.53%)

Check out this evening's…

ShowHide Related Items >><<
SAND Sandstorm Gold
$5.57 /

+0.19 (+3.53%)

MNMD Mind Medicine
$6.11 /

+0.37 (+6.45%)

IBIO iBio
/

+

GMDA Gamida Cell
$1.95 /

+0.03 (+1.56%)

FYBR Frontier Communications
$22.22 /

+0.895 (+4.20%)

CALM Cal-Maine Foods
$60.55 /

+0.8 (+1.34%)

BB BlackBerry
$5.09 /

+0.11 (+2.21%)

FYBR Frontier Communications
$22.22 /

+0.895 (+4.20%)

09/09/22 Credit Suisse
Frontier Communications initiated with a Neutral rating at Credit Suisse
05/26/22 Morgan Stanley
Frontier upgraded to Equal Weight from Underweight at Morgan Stanley
04/26/22 Citi
Frontier Communications initiated with a Buy at Citi
04/07/22 Wells Fargo
Frontier Communications initiated with an Overweight at Wells Fargo
IBIO iBio
/

+

11/29/21 JMP Securities
iBio initiated with an Outperform at JMP Securities
11/29/21 JMP Securities
iBio initiated with an Outperform at JMP Securities
IPW iPower
$1.05 /

+0.1115 (+11.88%)

02/15/22 DA Davidson
iPower price target lowered to $6 from $8 at DA Davidson
09/28/21 DA Davidson
iPower sales trends remain robust, says DA Davidson
BB BlackBerry
$5.09 /

+0.11 (+2.21%)

08/12/22 Baird
BlackBerry initiated with a Neutral at Baird
06/24/22 TD Securities
TD Securities cuts BlackBerry target to $5 after 'low-quality' beat
05/19/22 Canaccord
BlackBerry price target lowered to $6 from $7 at Canaccord
04/01/22 Canaccord
BlackBerry results in-line but guidance disappoints, says Canaccord
CALM Cal-Maine Foods
$60.55 /

+0.8 (+1.34%)

03/30/22 Consumer Edge
Cal-Maine Foods upgraded to Overweight from Equal Weight at Consumer Edge
MNMD Mind Medicine
$6.11 /

+0.37 (+6.45%)

09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
08/30/22 Oppenheimer
Mind Medicine price target raised to $52 from $3.50 at Oppenheimer
08/25/22 Oppenheimer
Mind Medicine initiated with an Outperform at Oppenheimer
08/18/22 H.C. Wainwright
MindMed rallying into activist group call today, says H.C. Wainwright
GMDA Gamida Cell
$1.95 /

+0.03 (+1.56%)

08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
05/10/22 Piper Sandler
Gamida Cell price target lowered to $6 from $13 at Piper Sandler
04/26/22 JMP Securities
JMP Securities reiterates Outperform on Gamida Cell as FDA lifts clinical hold
SAND Sandstorm Gold
$5.57 /

+0.19 (+3.53%)

08/17/22 BMO Capital
Sandstorm Gold upgraded to Outperform from Market Perform at BMO Capital
08/16/22 TD Securities
Sandstorm Gold price target raised to C$10.50 from C$10 at TD Securities
08/16/22 National Bank
Sandstorm Gold resumed with an Outperform at National Bank
07/20/22 Stifel
Sandstorm Gold price target lowered to C$13.50 from C$14 at Stifel
SAND Sandstorm Gold
$5.57 /

+0.19 (+3.53%)

MNMD Mind Medicine
$6.11 /

+0.37 (+6.45%)

IPW iPower
$1.05 /

+0.1115 (+11.88%)

IBIO iBio
/

+

GMDA Gamida Cell
$1.95 /

+0.03 (+1.56%)

FYBR Frontier Communications
$22.22 /

+0.895 (+4.20%)

CALM Cal-Maine Foods
$60.55 /

+0.8 (+1.34%)

BB BlackBerry
$5.09 /

+0.11 (+2.21%)

  • 28
    Sep
MNMD Mind Medicine
$6.11 /

+0.37 (+6.45%)

BB BlackBerry
$5.09 /

+0.11 (+2.21%)

SAND Sandstorm Gold
$5.57 /

+0.19 (+3.53%)

MNMD Mind Medicine
$6.11 /

+0.37 (+6.45%)

FYBR Frontier Communications
$22.22 /

+0.895 (+4.20%)

BB BlackBerry
$5.09 /

+0.11 (+2.21%)

SAND Sandstorm Gold
$5.57 /

+0.19 (+3.53%)

MNMD Mind Medicine
$6.11 /

+0.37 (+6.45%)

IBIO iBio
/

+

CALM Cal-Maine Foods
$60.55 /

+0.8 (+1.34%)

BB BlackBerry
$5.09 /

+0.11 (+2.21%)

Syndicate
Gamida Cell announces offering of ordinary shares, no amount given » 16:07
09/27/22
09/27
16:07
09/27/22
16:07
GMDA

Gamida Cell

$1.95 /

+0.025 (+1.30%)

Gamida Cell Ltd.…

Gamida Cell Ltd. announced the launch of a follow-on public offering of its ordinary shares. Gamida Cell intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and trading financial assets: to fund (i) commercial readiness activities to support potential launch of omidubicel, if approved; (ii) the continued clinical development of its NK product candidates, including GDA-201; and (iii) general corporate purposes, including general and administrative expenses and working capital. Piper Sandler & Co. and JMP Securities, a Citizens Company, are acting as joint book-running managers for this offering.

ShowHide Related Items >><<
GMDA Gamida Cell
$1.95 /

+0.025 (+1.30%)

GMDA Gamida Cell
$1.95 /

+0.025 (+1.30%)

08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
05/10/22 Piper Sandler
Gamida Cell price target lowered to $6 from $13 at Piper Sandler
04/26/22 JMP Securities
JMP Securities reiterates Outperform on Gamida Cell as FDA lifts clinical hold
GMDA Gamida Cell
$1.95 /

+0.025 (+1.30%)

Conference/Events
William Blair biotech analysts to hold analyst/industry webinar » 16:24
09/22/22
09/22
16:24
09/22/22
16:24
GMDA

Gamida Cell

$1.95 /

-0.1 (-4.88%)

Biotech Analysts, along…

Biotech Analysts, along with Chief Medical & Chief Scientific Officer Simantov of Gamida Cell, discuss innovations in hematopoietic stem cell transplantation on an Analyst/Industry webinar to be held on September 29 at 3 pm. Webcast Link

ShowHide Related Items >><<
GMDA Gamida Cell
$1.95 /

-0.1 (-4.88%)

GMDA Gamida Cell
$1.95 /

-0.1 (-4.88%)

08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
05/10/22 Piper Sandler
Gamida Cell price target lowered to $6 from $13 at Piper Sandler
04/26/22 JMP Securities
JMP Securities reiterates Outperform on Gamida Cell as FDA lifts clinical hold
GMDA Gamida Cell
$1.95 /

-0.1 (-4.88%)

Hot Stocks
Gamida Cell CEO Julian Adams to retire, Abigail Jenkins to succeed » 07:03
09/19/22
09/19
07:03
09/19/22
07:03
GMDA

Gamida Cell

$2.42 /

-0.155 (-6.03%)

Gamida Cell announced…

Gamida Cell announced that Abigail Jenkins has joined as president and CEO. Jenkins has also been appointed to Gamida Cell's board of directors. Jenkins succeeds Julian Adams, who is retiring in accordance with planned succession and will continue to serve on the company's board of directors. Jenkins brings over 20 years of experience in the biopharmaceutical industry. She served as the chief commercial and business officer at Lyndra Therapeutics, where she established and led global commercial, business development, corporate strategy and portfolio management across multiple therapeutic areas.

ShowHide Related Items >><<
GMDA Gamida Cell
$2.42 /

-0.155 (-6.03%)

GMDA Gamida Cell
$2.42 /

-0.155 (-6.03%)

08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
05/10/22 Piper Sandler
Gamida Cell price target lowered to $6 from $13 at Piper Sandler
04/26/22 JMP Securities
JMP Securities reiterates Outperform on Gamida Cell as FDA lifts clinical hold
GMDA Gamida Cell
$2.42 /

-0.155 (-6.03%)

Over a month ago
Recommendations
Gamida Cell price target raised to $8 from $6 at Piper Sandler » 11:11
08/15/22
08/15
11:11
08/15/22
11:11
GMDA

Gamida Cell

$3.10 /

+0.1 (+3.33%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Gamida Cell to $8 from $6 and keeps an Overweight rating on the shares. The FDA has set a PDUFA date of January 30 for omidubicel for allogeneic hematopoietic stem cell transplant, or aHSCT, and he remains confident in omidubicel approval based on positive Phase 3 data, said Tenthoff, who cites decreasing his discount rate on omidubicel and rolling forward his discount period to mid-2023 for his increased price target.

ShowHide Related Items >><<
GMDA Gamida Cell
$3.10 /

+0.1 (+3.33%)

GMDA Gamida Cell
$3.10 /

+0.1 (+3.33%)

08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
05/10/22 Piper Sandler
Gamida Cell price target lowered to $6 from $13 at Piper Sandler
04/26/22 JMP Securities
JMP Securities reiterates Outperform on Gamida Cell as FDA lifts clinical hold
01/19/22 H.C. Wainwright
Gamida Cell remains top pick with omidubicel on track, says H.C. Wainwright
GMDA Gamida Cell
$3.10 /

+0.1 (+3.33%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.